How effective is Sotoracib (AMG510) in advanced cancer?

Sotoracib (AMG510), also known as AMG 510, is a targeted therapy for the KRAS G12C mutation. This mutation is one of the most common in advanced non-small cell lung cancer (NSCLC). Sotorasiib works by inhibiting the KRAS G12C mutant protein, which plays an important role in the development of NSCLC. By inhibiting this protein, sotoraxib can block the growth and spread of tumors, thereby achieving the effect of treating lung cancer.

In a major study involvingsotorasiib was effective in adults with KRAS G12C gene-mutated non-small cell lung cancer whose disease had progressed after prior treatment with other cancer drugs. Sotorasiib was not compared with any other treatment or placebo (dummy treatment). Body scans are used to assess response to treatment (reduction in cancer size). About 37% (46 of 124 patients) showed partial or complete cancer shrinkage after treatment with sotoraxib. On average the duration is over 11 months.

Although sotoracib has shown promise in the treatment of advanced non-small cell lung cancer, more clinical studies are needed to further verify its safety and efficacy. In addition, this drug may cause some side effects, such as fatigue, nausea, vomiting, etc. Therefore, your doctor's instructions should be followed when using sotoraxib, and patients should be monitored closely.

In short, sotorasiib, as a targeted therapy drug targetingKRAS G12C mutation, has shown certain effects in the treatment of advanced non-small cell lung cancer. However, further research and observations are needed to better understand its efficacy and safety.